TYK2 and psoriasis: Considering the high physiological similarities between mice and men concerning TYK2 deficiency [4, 24, 140], loss of TYK2 enzymatic activity [3, 30] and genetic versus pharmacologic TYK2 inhibition [67, 134] our data are also relevant in light of the patient cohort with inborn TYK2 impairments [141] and the treatment of psoriasis and several ongoing clinical trials for other autoimmune and inflammatory diseases with respect to hitherto overseen tissue and cell-type-specific effects and potential epigenomic and post-transcriptional effects [142–144].